Skip to content

Study · Systematic review · 2022

2 results

Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.

Zhao G, Zhang Q, Wu F, Yin S, Xie Y, Liu H

Expert review of clinical pharmacology7 Sept 2022Cited by 12 (Europe PMC)

PMID36039827 (opens in a new tab)DOI10.1080/17512433.2022.2117152 (opens in a new tab)PepBankPUB-36039827
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In children with obesity, a Bayesian network meta-analysis found that liraglutide reduced BMI the most compared with the other drugs analysed.

    In plain wordsIn children with obesity, liraglutide lowered BMI more than the other drugs in a pooled analysis of trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI reduction ranking
    Study

    n: not reported in source

    Comparator
    Other drugs in the network
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to other drugs, liraglutide reduced BMI the most in children with obesity.
    2 context sentences
    Summary · context
    This meta-analysis focused on the slimming effect, safety, and correlation of metformin, orlistat, exenatide, liraglutide, and topiramate in children with obesity.
    Summary · context
    Of 2102 relevant articles retrieved, 21 RCTs were included in the study.
  2. 02HumanSystematic reviewSafety outcome

    In children with obesity, liraglutide was the drug most associated with withdrawal due to adverse events in the network meta-analysis, while topiramate was least.

    In plain wordsIn children with obesity, more people stopped liraglutide because of side effects than the other drugs in a pooled analysis.

    Peptide
    Liraglutide
    Outcome
    IncreaseDrug withdrawal due to adverse events
    Study

    n: not reported in source

    Comparator
    Other drugs in the network
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, it was most associated with drug withdrawal due to adverse events while topiramate was least.
    2 context sentences
    Summary · context
    This meta-analysis focused on the slimming effect, safety, and correlation of metformin, orlistat, exenatide, liraglutide, and topiramate in children with obesity.
    Summary · context
    Of 2102 relevant articles retrieved, 21 RCTs were included in the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.